November 6, 2025 • 2 mins
Soligenix Inc., trading as SNGX on NASDAQ, is advancing in the dermatology sector with SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis. Early phase 2a trial results indicate promising safety and efficacy, positioning SGX302 as a potential well-tolerated treatment for psoriasis. Soligenix aims to capitalize on the growing $67 billion market opportunity by expanding its presence in dermatology, with ongoing trials potentially leading to regulatory approval and commercialization, highlighting the company's dedication to addressing unmet medical needs in rare diseases.
Mark as Played
Popular Podcasts
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.